CGON
CG OncologyCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-22
Current thesis
Successful clinical readouts or a strategic partnership could rapidly re-rate the stock toward premium growth multiples; market attention would likely amplify upside given limited public float and concentrated event risk [#SERP-1].
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +1.6.
What can break
Clinical readout failure or delay
Momentum
81
Value
41
Sentiment
39
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $63.80 · Bull $88.77 · Bear $38.84
Data freshness
Prices
As of 2026-07-22
Fundamentals
As of 2026-07-21 • Vendor: Data Vendor v1
Scores
As of 2026-07-22 • Model: HYBRID_IC_RP
AI Memo
As of 2026-01-10 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-22
Investment thesis
As of 2026-07-22
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $90.69
Why
Momentum81 · Δ7d +1.6
Value41 · Δ7d -0.0
Sentiment39 · Δ7d -0.4
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
81
26% active weight
Current posture
7d trendSoftening
Δ7d
+1.6
Δ21d
+13.3
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-0.1
Sentiment
39
34% active weight
Current posture
7d trendFlat
Δ7d
-0.4
Δ21d
-2.6
Why this grade
Composite grade C. Momentum 81.1 / Value 41.1 / Sentiment 38.8
Fundamentals (TTM)As of 2026-07-21
Fundamentals (TTM)
As of 2026-07-21
Market Cap
$6.33B
Beta
-
Shares Out
88.2M
P/E (TTM) · Derived
-34.4
P/S (TTM)
1485.68
P/FCF (TTM) · Derived
-35.78
Rev YoY
+1982.7%
EPS YoY
+57.5%
Gross Margin
-63.1%
Op Margin
-8285.3%
Net Debt
-$735.13M
Current Ratio
31.30
As of 2026-07-22 • Updated nightlySource: Internal modelMethodology